RxDoctor Payments Data

Nancy Allegar, MD

Internal Medicine · Hillsborough, NJNPI 1750387494

Payments from drug & device makers

$1,205in general payments, 2019–2025

Across 93 payments — averaging $12.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$433
  • AstraZeneca$339
  • Sanofi-aventis U.S. LLC$80
  • AbbVie$55
  • Sanofi$41
  • Merck$40
  • plus $217 from 13 others

What the payments were for

  • Food & beverage$1,12593%
  • Education$807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,205 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$293,811
Medicare patients
347
Services billed
4,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide153$195,402
XolairOmalizumab36$193,079
WegovySemaglutide23$36,545
EliquisApixaban28$34,722
JardianceEmpagliflozin42$33,993
JanuviaSitagliptin Phosphate30$33,468
MounjaroTirzepatide15$32,567
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$27,639
MyrbetriqMirabegron27$25,933
DuleraMometasone/Formoterol45$23,573
SynthroidLevothyroxine Sodium234$20,849
Janumet XrSitagliptin Phos/Metformin Hcl13$19,021
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,617
Breo ElliptaFluticasone/Vilanterol32$12,497
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$11,537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$433$231,946176 claims
MerckJanuvia, Dulera, Janumet Xr$40$76,06288 claims
PfizerEliquis, Premarin$25$44,92154 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Nexium$339$42,28293 claims
Boehringer IngelheimJardiance$13$33,99342 claims
GSKTrelegy Ellipta, Breo Ellipta$15$29,11348 claims
Astellas Pharma US IncMyrbetriq$14$25,93327 claims
AbbVieSynthroid$55$20,849234 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$24$2,13620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Hillsborough

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →